Drug Trial Radar · NCT00209456
Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia
Last checked: Nov 20, 2026Latest source record: May 16, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
326
Actual
Start
Nov 2003
Primary completion
Not stated
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- First posted
- Sep 21, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- All sexes, from 55 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to determine the diagnostic efficacy of the visual assessment of SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects determined by the clinical diagnosis of an independent expert consensus panel used as the standard of truth.
Conditions
- Lewy Body Dementia
- Non-DLB Dementia
- Alzheimer's
- Vascular Dementia
Interventions
DatSCANDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sensitivity and specificity of DaTSCAN SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Amersham Buchler GmbH Co. KG
Ismaning, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.